Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352844 · ClinicalTrials.gov registry record · Phase 2
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
A Phase 2 study of Solid Tumor and Solid Malignancy, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02352844 is a Phase 2 study of Solid Tumor and Solid Malignancy that has completed, run by Washington University School of Medicine. The registered enrollment target is 12 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02352844, a Phase 2 study of Solid Tumor and Solid Malignancy, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to look at participants with solid tumor malignancies and specific mutations respond to treatment with everolimus.
Conditions Studied
Interventions
- DRUG Everolimus
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-10-07 |
| Est. Completion | 2017-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352844
The ClinicalTrials.gov registry entry for NCT02352844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (95% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Everolimus is the first listed.
NCT02352844 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02352844 about?
NCT02352844 is a clinical study titled "Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations". The purpose of this research study is to look at participants with solid tumor malignancies and specific mutations respond to treatment with everolimus.
What is the current status of trial NCT02352844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2015-10-07. Estimated completion is 2017-08-15.
What conditions does trial NCT02352844 study?
This clinical trial studies the following conditions: Solid Tumor, Solid Malignancy.
What interventions are being tested in trial NCT02352844?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT02352844?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02352844 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.